Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Cyberfort Software, Inc.Financial_Report.xls
EX-31.2 - CERTIFICATION - Cyberfort Software, Inc.gaia_ex312.htm
EX-31.1 - CERTIFICATION - Cyberfort Software, Inc.gaia_ex311.htm
EX-32.1 - CERTIFICATION - Cyberfort Software, Inc.gaia_ex321.htm


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

____________________________

 

FORM 10-Q

____________________________


[X]  QUARTERLY REPORT PURSUANT SECTION 13 OR 15(D) OF THE SECURITIES

EXCHANGE ACT OF 1934


For the quarterly period ended June 30, 2012


[  ]  TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934


For the transition period from _______________ to _______________

 

Commission File # 333-174894

 

GAIA REMEDIES, INC.

(Exact name of small business issuer as specified in its charter)

 

Nevada

(State or other jurisdiction of incorporation or organization)

 

38-3832726

(IRS Employer Identification Number)


13140 70th Lane NE, Kirkland, Washington 98034

 (Address of principal executive offices)


(425) 224-2471

(Issuer’s telephone number)


Indicate by check mark whether the registrant(1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 day. [X] Yes    [ ] No


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.





 




Large accelerated filer [  ]

Accelerated filer [  ]

Non-accelerated filer [  ]

(Do not check if a smaller reporting company)

Smaller reporting company []



Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). [X] Yes    [  ] No

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. The issuer had 5,557,500 shares of common stock issued and outstanding as of August 13, 2012.




























2



 PART I - FINANCIAL INFORMATION

 

ITEM 1.  FINANCIAL STATEMENTS


GAIA REMEDIES, INC.

(A DEVELOPMENT STAGE COMPANY)

BALANCE SHEETS

As of June 30, 2012 and March 31, 2012



ASSETS

June 30,

2012

(unaudited)

March 31, 2012

Current assets

 

 

  Cash

$      8,070

$    12,686

Total current assets

8,070

12,686

Total assets

$      8,070

$    12,686

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

Current liabilities

 

 

  Accounts payable and accrued liabilities

$      2,700

$              -

Total current liabilities

2,700

-

Total liabilities

2,700

-

 

 

 

Commitments

 

 

 

 

 

STOCKHOLDERS’ EQUITY

 

 

  Common stock, $.001 par value, 100,000,000 shares authorized, 5,557,500 shares issued and outstanding


5,558


5,558

  Additional paid in capital

40,992

40,992

  Deficit accumulated during the development stage

(41,180)

(33,864)

Total stockholders’ equity

5,370

12,686

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$     8,070

$    12,686







See accompanying notes to financial statements.



3




GAIA REMEDIES, INC.

(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF OPERATIONS

For the three months ended  June 30, 2012 and 2011

for the period from December 15, 2010 (Inception) through June 30, 2012

(unaudited)



 

Three

months

ended June 30, 2012

Three months ended June 30, 2011

Inception through

June 30, 2012

General and administrative expenses:

 

 

 

    Professional fees

 $     6,128

 $    14,304

 $     35,396

    Other

 1,188

 1,069

 5,784

Total general and administrative expenses

 7,316

 15,373

 41,180

 

 

 

 

Net loss

 $   (7,316)

 $   (15,373)

 $   (41,180)

 

 

 

 

Net loss per share:

 

 

 

  Basic and diluted

$   (0.00)

$   (0.00)

 

 

 

 

 

 Weighted average shares outstanding:

 

 

 

    Basic and diluted

 5,557,500

5,557,500

 



 











See accompanying notes to financial statements.




4




GAIA REMEDIES, INC.

(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF CASH FLOWS

For the three months ended June 30, 2012 and 2011

for the period from December 15, 2010 (Inception) through June 30, 2012

(unaudited)



 

Three months ended June 30, 2012

Three months ended June 30, 2011

Inception through June 30, 2012

CASH FLOWS FROM OPERATIONS

 

 

 

Net loss

$      (7,316)

$     (15,373)

$    ( 41,180)

Adjustments to reconcile net loss to cash used by operating activities

 

 

 

Increase in accrued expenses

2,700

5,718

2,700

CASH FLOWS USED IN OPERATING ACTIVITIES

(4,616)

(9,655)

(38,480)

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

  Proceeds from sale of common stock

-

-

46,550

 

 

 

 

CASH FLOWS PROVIDED BY FINANCING ACTIVITIES

-

-

46,550

 

 

 

 

NET CHANGE IN CASH

(4,616)

(9,655)

8,070

 

 

 

 

Cash, beginning of  period

12,686

41,822

-

Cash, end of period

$         8,070

$       32,167

$         8,070

 

 

 

 

SUPPLEMENTAL CASH FLOW INFORMATION  

 

 

 

  Interest paid

$                 -

$                 -

$                 -

  Income tax paid

$                 -

$                 -

$                 -








See accompanying notes to financial statements.




5




GAIA REMEDIES, INC.

(A DEVELOPMENT STAGE COMPANY)

NOTES TO THE FINANCIAL STATEMENTS

June 30, 2012

(unaudited)


NOTE 1  - NATURE OF BUSINESS


Nature of Business


Gaia Remedies, Inc. (“Gaia” or the “Company”) was incorporated in Nevada on December 15, 2010. Gaia is in the business of the online retail sale of all natural pet remedies. Gaia is a development stage company and has not yet realized any revenues from its planned or any other operations.


The accompanying unaudited interim financial statements have been prepared by the Company pursuant to the rules and regulations of the United States Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K. Certain information and disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments and disclosures necessary for a fair presentation of these financial statements have been included.  Such adjustments consist of normal recurring adjustments. Operating results for the three months ended June 30, 2012 are not necessarily indicative of the results that may be expected for the full year ending March 31, 2013.


NOTE 2 - GOING CONCERN


Gaia has a loss and has a deficit accumulated during the development stage of $41,180 as of June 30, 2012.  Gaia's financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  However, Gaia has no current source of revenue, which raises substantial doubt about the Company’s ability to continue as a going concern. Without realization of additional capital, it would be unlikely for Gaia to continue as a going concern.  Gaia’s management plans on raising cash from public or private debt or equity financing, on an as needed basis and in the longer term, revenues from the operations of its online retail business. Gaia’s ability to continue as a going concern is dependent on these additional cash financings, and, ultimately, upon achieving profitable operations through the operation of its online retail business or otherwise.


NOTE 3 - ADVANCE FROM SHAREHOLDER


A shareholder of the Company has offered a shareholder loan facility up to $100,000.  The loan facility is unsecured and bears interest at 5% per annum and is payable on demand after June 30, 2013. As of June 30, 2012, the amount outstanding under the shareholder loan facility was $ nil.



6




ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION  


Forward-looking statements


This quarterly report on Form 10-Q contains "forward-looking statements" relating to the registrant which represent the registrant's current expectations or beliefs, including statements concerning registrant’s operations, performance, financial condition and growth.  For this purpose, any statement contained in this quarterly report on Form 10-Q that are not statements of historical fact are forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "anticipation", "intend", "could", "estimate", or "continue" or the negative or other comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, such as credit losses, dependence on management and key personnel and variability of quarterly results, ability of registrant to continue its growth strategy and competition, certain of which are beyond the registrant's control. Should one or more of these risks or uncertainties materialize or should the underlying assumptions prove incorrect, actual outcomes and results could differ materially from those indicated in the forward-looking statements.


The following discussion and analysis should be read in conjunction with the information set forth in the Company’s audited financial statements for the period ended March 31, 2012.


Overview


We are a development stage company with plans to enter into the business of the online retail sale of herbal and homeopathic pet remedies, healthy organic pet treats and pet accessories. We plan to sell products consisting of a wide variety of healthy living and wellness products for animals, such as vitamins, dietary supplements, herbal tinctures, flower remedies, homeopathic remedies, as well as pet treats like: chicken, liver, and beef dog treats, bully sticks and dog chews. We intend to sell these products through an internet website located at www.gaiaremedies.com (the "Website").


Our company, based in Kirkland, Washington, was incorporated under the laws of Nevada on December 15, 2010. Our principal executive offices are located at 13140 70th Lane NE, Kirkland, Washington and our telephone number is (425) 224-2471. Our website address is www.gaiaremedies.com.


Plan of Operation


Our plan of operation is to finish construction of our website and commence selling our product line.




7




Results of Operations


Three Months Ended June 30, 2012


Revenues


We did not generate any revenues during the reporting period.


Expenses


We incurred operating expenses in the amount of $7,316 during the three months ended June 30, 2012 compared to $15,373 for the corresponding period in 2011.


Net Loss


We incurred a net loss of $7,316 during the three months ended June 30, 2012, compared to a net loss of $15,373 for the corresponding period in 2011.  


LIQUIDITY AND CAPITAL RESOURCES


Since its inception, the Company has financed its cash requirements from the sale of common stock. Uses of funds have included activities to establish our business, professional fees and other general and administrative expenses.


The Company’s principal sources of liquidity as of June 30, 2012 consisted of $8,070 in cash and cash equivalents and a shareholder loan facility up to $100,000 from a director and principal shareholder.


Under the shareholder loan facility from Peter P. Hedly, loan advances to or on behalf of the Company bear interest at 5% per annum. The Company is required to repay the outstanding principal and interest at any time after June 30, 2013, on demand. Prepayment of all or a portion of the outstanding principal and interest may be made by the Company at any time without notice, bonus or penalty.


The amount outstanding under shareholder loan facilities was $ nil as of June 30, 2012.


We believe the Company will have adequate resources to implement its strategic objectives in upcoming quarters. Due to our lack of operating history and present inability to generate revenues, however, our auditors have stated their opinion that there currently exists substantial doubt about our ability to continue as a going concern.


Material Events and Uncertainties


Our operating results are difficult to forecast. Our prospects should be evaluated in light of the risks, expenses and difficulties commonly encountered by comparable exploration stage companies.



8




There can be no assurance that we will successfully address such risks, expenses and difficulties.


ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.


We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.


ITEM 4. CONTROLS AND PROCEDURES


Disclosure controls and procedures

 

As of the end of the period covered by this report (the “Evaluation Date”), the Company carried out an evaluation, under the supervision and with the participation of the Company's Principal Executive Officer and Principal Financial Officer (the “Certifying Officers”) of the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e)) under the Exchange Act. Based on that evaluation, the Certifying Officers have concluded that, as of the Evaluation Date, the disclosure controls and procedures in place were adequate to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported on a timely basis in accordance with applicable rules and regulations.


Internal control over financial reporting


The Certifying Officers reviewed our internal control over financial reporting (as defined in rules 13a-15(f) and 15d-15(f)) under the Exchange Act as of the Evaluation Date and concluded that no changes occurred in such control or in other factors during the quarter ended June 30, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.



PART II - OTHER INFORMATION


ITEM 1. LEGAL PROCEEDINGS


There is no litigation pending or threatened by or against us.


ITEM 1A. RISK FACTORS


We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.


ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS


The Company did not make any sales of equity securities during the quarter.



9




ITEM 3. DEFAULTS UPON SENIOR SECURITIES


The Company has no senior securities outstanding.


ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS


During the quarter ended June 30, 2012, no matters were submitted to a vote of the Company's security holders, through the solicitation of proxies or otherwise.


ITEM 5. OTHER INFORMATION


(a) No matters arose during the quarter which required the Company to report any information through the filing of a current report on Form 8-K.


(b) During the quarter there were no material changes to the procedures by which security holders may recommend nominees to the registrant’s board of directors.


ITEM 6. EXHIBITS


Number

Exhibit Description

 

 

3.1

Articles of Incorporation of Gaia Remedies, Inc. *

 

 

3.2

Bylaws of Gaia Remedies, Inc.*

 

 

31.1

Certificate of principal executive officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

31.2

Certificate of principal financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

32.1

Certificate of principal executive officer and principal financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


*    Filed as an exhibit to our registration statement on Form S-1 filed June 15, 2011 and incorporated herein by this reference







10




SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


GAIA REMEDIES, INC.


/s/  Peter P. Hedly

Peter P. Hedly

President (Principal Executive Officer) and Treasurer (Principal Financial Officer)


August 13, 2012














11